← Astellas Pharma (ALPMY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Astellas Pharma (ALPMY)
Healthcare · market cap $27.2B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Astellas Pharma (ALPMY) is a large Japanese healthcare company with 13,643 employees and a market capitalization of approximately $24.1B. The company fields an unusually broad pipeline spanning oncology, transplantation, infectious disease, and neurology, with multiple Phase 3 assets including OPT-80 (C. difficile), Setidegrasib (pancreatic cancer), and several transplant-immunology programs. Near-term disclosed catalysts are Phase 2 readouts for nab-paclitaxel and leucovorin combination regimens, both estimated by end of 2026.
The catalyst path
- 2026-12-15 (est.)Phase 2 · ZEN003694imp 7/10
- 2026-12-16 (est.)Phase 2 · Enfortumab vedotinimp 7/10
- 2026-12-30 (est.)Phase 2 · XNW27011imp 7/10
- 2026-12-31 (est.)Phase 3 · NSAAimp 9/10
- 2027-03-15 (est.)Phase 2 · Enfortumab vedotinimp 7/10
- 2027-05-15 (est.)Phase 2 · Enzalutamideimp 7/10
- 2027-06-02 (est.)Phase 2 · Enfortumab vedotinimp 7/10
- 2027-06-30 (est.)Phase 2 · zolbetuximabimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| OPT-80 | Phase 3 | Clostridium Difficile |
| Setidegrasib | Phase 3 | Pancreatic Cancer |
| Vernakalant Injection 20 mg/mL | Phase 3 | Atrial Flutter |
| daclizumab | Phase 3 | Kidney Transplantation |
| ASP1650 | Phase 2 | Incurable Platinum Refractory Germ Cell Tumors |
| YM177 | Phase 3 | Post Operative Pain |
| Erlotinib | Phase 3 | NSCLC |
| micafungin (Mycamine) | Phase 3 | Fungemia |
| VESIcare® | Phase 3 | Urinary Bladder, Overactive |
| YM872 (zonampanel), t-PA (alteplase) | Phase 2 | Acute Ischemic Stroke |
| CZP | Phase 3 | Rheumatoid Arthritis |
| ASP4070 | Phase 2 | Rhinitis, Allergic, Seasonal |
| ASP4901 | Phase 2 | Benign Prostate Hyperplasia |
| Tacrolimus Inhalation Aerosol | Phase 2 | Asthma |
| ASP2998 | Phase 2 | Locally Advanced or Metastatic Malignant Solid Tumors |
| Liposomal Amphotericin B | Phase 3 | Candidiasis |
| YM529 / ONO-5920 | Phase 3 | Osteoporosis |
| Ramosetron | Phase 3 | Vomiting |
| ASP5541 | Phase 2 | Prostate Cancer |
| Advagraf | Phase 3 | Heart Transplantation |
Price & technical context
3-month
+8.6%
6-month
-13.9%
12-month
+32.7%
52-wk range
$10.28–$16.78
vs 50-day MA
-1.3%
vs 200-day MA
-0.8%
Realized vol
29.8%
Max drawdown
-29.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ALPMY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.